Sky Valley Advisors partners with pre-clinical and clinical stage biotech CEOs, executives, and boards on the functions that would otherwise require a larger team across strategy, finance, capital advisory, and operations.
30+
clinical-stage and AMC engagements
40+
years across biotech, oncology, cell & gene therapy, AI drug discovery
100+
transactions supported across the team's careers
10,000+
hours working alongside senior leaders to advance assets and technologies
Most boutique biotech advisors come from one path — banking, strategy consulting, science, or operations. My background pulls from several of them. The result is fluency across the clinical paper, the use-of-proceeds slide, and the term sheet in the same conversation.
The strategic timeline, the financial model, the pitch deck, the target list, and the term sheet read sit with one team. No re-briefing four advisors. The work compounds across functions because it's the same hands doing it.
Some engagements wrap in 90 days; others run for multiple quarters. The long ones aren't bigger — they're sharper, because by the second quarter the model, the narrative, and the investor list are warm.
Our clients are typically at the pre-IND or clinical stage, working in one of four areas of advanced therapeutics.
CAR-T, iPSC platforms, and regenerative medicine. Build-vs-partner manufacturing decisions, point-of-care vs centralized supply chain, and the financing pathways that fund clinical-stage development.
Antibody drug conjugates, bispecifics, and next-generation oncology biologics. Asset diligence, comparable benchmarking, PIPE and IPO readiness for clinical-stage and public-stage programs.
Platform companies whose discovery engine is the asset. Seed and Series A narratives, defensibility of the platform, partnership economics, and the path from compute to clinic.
Comprehensive cancer centers, children's hospitals, and academic medical centers spinning up cell and gene therapy capabilities. Growth strategies, market sizing, operating and financial models for GMP cores and trial enrollment.
Most engagements fit one of these archetypes. Many span more than one over time.
Pre-Series A/B teams who know they're raising soon.
Strategic timeline, FP&A model, use-of-proceeds, pitch deck, investor target list, data room setup.
Clinical-stage companies between rounds.
Ongoing fractional engagement — financial model, board materials, BD support, IR, project management, monthly cadence with the executive team.
Pre-IND to Phase 2 teams weighing indications, sequencing, and where to invest next.
Target product profile, indication prioritization, development plan, go/no-go criteria, and a board-ready strategy narrative.
Boards, AMCs, F500 biotech, or PE-backed mid-market companies with a specific question.
Discrete project — market sizing, build/partner decision, competitive landscape, GMP or manufacturing assessment, target diligence.
Most clinical-stage companies have a development plan, a runway forecast, and a fundraising thesis. The hard work is making sure all three say the same thing. Our approach is to build a single integrated timeline — clinical milestones, cash burn, and capital events on one canvas — and use it as the operating model for the engagement. When the science slips a quarter, the financing strategy adjusts in the same conversation, not three weeks later.
Read more about how we workLet's talk about how we could help. A 30-minute intro call is the fastest way to see if there's a fit.
Book a 30-minute intro